围手术期使用质子泵抑制剂对合并骨质疏松或骨量减少的全关节置换术患者结局的影响
本研究利用大型国家数据库回顾性比较合并骨质疏松/骨量减少的全髋/全膝关节置换患者围手术期使用与未使用质子泵抑制剂的结局。经倾向评分1:1匹配后,全髋置换每组3370例、全膝置换每组7521例,术后2年和5年翻修率及并发症率两组相似。作者认为短期使用质子泵抑制剂在该高危人群中看似安全,但需进一步研究评估长期结局。
要点
- 合并骨质疏松/骨量减少的全髋置换患者围手术期使用质子泵抑制剂后2年全因翻修率3.6%、5年4.4%,与未使用组相似。
- 合并骨质疏松/骨量减少的全膝置换患者围手术期使用质子泵抑制剂后2年全因翻修率2.4%、5年3.7%,两组结局无显著差异。
- 作者认为全关节置换术后短期使用质子泵抑制剂用于胃肠道预防在该高危人群中看似安全,但需进一步研究评估长期结局。
核心结论
- 在合并骨量减少和骨质疏松的全关节置换患者中,围手术期使用质子泵抑制剂者与未使用者术后2年和5年并发症率均较低且相似。
- 作者认为全关节置换术后短期使用质子泵抑制剂用于胃肠道预防在该较高风险人群中看似安全,但需进一步研究评估长期结局。
研究设计与样本
- 基于大型国家数据库的回顾性研究,纳入接受全髋或全膝关节置换的骨质疏松/骨量减少患者,排除长期术前使用质子泵抑制剂者。
- 按围手术期(术前30天至术后7天)是否填写质子泵抑制剂处方分组,两组经1:1倾向评分匹配,比较术后2年和5年结局。
- 全髋置换分析匹配后每组3370例,全膝置换分析匹配后每组7521例。
主要发现
- 全髋置换患者2年全因翻修率为3.6%、5年为4.4%,两组在2年和5年的翻修、无菌性松动/机械失败、假体周围骨折、脱位/不稳、手术部位感染(仅评估2年)及假体周围关节感染(仅评估2年)发生率相似。
- 全膝置换患者2年全因翻修率为2.4%、5年为3.7%,两组在术后2年或5年观察到的结局均无显著差异。
临床怎么用
- 作者认为全关节置换术后短期使用质子泵抑制剂用于胃肠道预防在合并骨量减少/骨质疏松的较高风险人群中看似安全,但需进一步研究评估长期结局。
局限性
- 原文结论指出需进一步研究评估长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Proton pump inhibitors (PPIs) are commonly prescribed for gastrointestinal prophylaxis after total joint arthroplasty (TJA) during periods of increased nonsteroidal anti-inflammatory drug/aspirin use. However, studies have shown negative effects of PPIs on osseointegration, potentially leading to increased risk of implant-related complications, particularly among patients who have decreased bone density. The present investigation utilizes a large national database to compare outcomes between osteoporotic/osteopenic TJA patients who received routine prophylactic perioperative PPIs and those who did not. METHODS: A retrospective review of patients who have osteoporosis/osteopenia undergoing total hip/knee arthroplasty (THA/TKA) in the database was performed. Long-term preoperative users of PPIs were excluded. Patients were classified based on whether or not they filled a PPI prescription perioperatively (30 days preoperatively to seven days postoperatively). The PPI and no-PPI groups were 1:1 propensity-score matched, and outcomes were compared at two and five years postoperatively. In the THA analysis, 3,370 patients were included in each group after matching. In the TKA analysis, 7,521 patients were included in each group. RESULTS: In THA patients, the all-cause revision rate was 3.6% at two years and 4.4% at five years. At two and five years, both groups experienced similar rates of revision, aseptic loosening/mechanical failure, periprosthetic fracture, dislocation/instability, surgical site infection (assessed at two years only), and periprosthetic joint infection (assessed at two years only). In TKA patients, the all-cause revision rate was 2.4% at two years and 3.7% at five years. There were no significant differences in outcomes observed between groups at two or five years postoperatively. CONCLUSIONS: In osteopenic and osteoporotic patients undergoing TJA, rates of 2- and 5-year postoperative complications were low and similar among patients who used PPIs perioperatively and those who did not. The short-term use of PPIs for gastrointestinal prophylaxis after TJA appears safe among this higher risk population, but further study is warranted to evaluate long-term outcomes.
引用
- Le A, Brennan JC, Johnson AH, et al. Effects of Perioperative Proton Pump Inhibitor Use on Outcomes of Total Joint Arthroplasty Patients Who Have Osteoporosis and Osteopenia. J Arthroplasty. 2025. PMID: 40780490. doi:10.1016/j.arth.2025.07.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。